-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, with the advancement of medical reform policies such as consistency evaluation and centralized procurement, the innovation and transformation of the pharmaceutical industry has become a trend.
Under this background, the number of domestic biomedical innovation companies has increased day by day, and the research and development of new drugs has high R&D investment, high risk, and payback period.
In order to solve the dilemma of insufficient innovation, more and more pharmaceutical companies have introduced innovative projects through the "authorized introduction" model to further enrich their product lines in addition to independent research and development
.
It is understood that since September, many pharmaceutical companies have introduced a variety of innovative drugs from outside
.
For example, on September 28th, Cinda Bio announced that it has reached a strategic cooperation with unio Therapeutics on unio's main drug candidate orismilast for the treatment of inflammatory skin diseases
.
According to the terms of the agreement, Cinda Bio will obtain the exclusive rights to research, development and commercialization of orismilast in China
.
unio will receive a down payment of 20 million U.
S.
dollars and is entitled to a cumulative milestone payment of no more than 247 million U.
S.
dollars, as well as royalties for the annual net sales of orismilast in China
.
Haisco announced on the evening of September 13 that the company and Biosplice Therapeutics, Inc.
of the United States signed a cooperation agreement with Lorecivivint, a candidate for a long-term treatment of osteoarthritis
.
According to the agreement, Haisco obtained the exclusive right to be responsible for Lorecivivint's development, registration and commercialization activities in China
.
To this end, Haisco will pay Biosplice US$20 million in down payment and registration mileage, as well as certain commercial mileage and royalties based on future sales, with a total transaction amount of US$140 million
.
On September 16, Saisheng Pharmaceuticals announced that the company has reached a cooperation and licensing agreement with Tarveda Therapeutics, which will serve as the latter's exclusive partner in the development, production and commercialization of Greater China (including China, Hong Kong, Macau and Taiwan) New product portfolio of small molecule conjugated drugs
.
According to the agreement, Saisheng Pharmaceutical will pay a down payment to Tarveda and have the right to make equity investment in the latter
.
According to the statistics of Minai.
com, since 2021, there have been more than 90 domestic innovative drug license in projects, of which more than 30 transactions exceeded 100 million U.
S.
dollars, and 14 exceeded 300 million U.
S.
dollars
.
The industry pointed out that license in has become one of the rapid development methods for many innovative pharmaceutical companies, which has also made the “authorized introduction” model of innovative drugs popular
.
However, such pharmaceutical companies also face many tests, including their ability to judge drugs and BD levels, as well as domestic clinical advancement and sales capabilities
.
It is also worth mentioning that the regulators and the market have also been quite cautious about the license in mode
.
In September of this year, Haihe Pharmaceutical's IPO was officially rejected
.
Within a week, GK Gene's IPO was also rejected
.
Since the beginning of this year, the number of biomedical entrepreneurs who terminated the IPO on the Sci-tech Innovation Board has increased to 14
.
Judging from the Shanghai Stock Exchange’s announcement, the supervisory authority has doubts about the “scientific innovation content” of Jikai Gene and Haihe Medicine, and believes that the issuer has not fully disclosed its independent research and development capabilities and technological advancement
.
In this regard, the industry believes that under the background of emphasizing "hard technology", in the future, it will be difficult for biopharmaceutical companies with a lack of scientific and technological innovation to go public.
Only biopharmaceutical companies that focus on innovation capabilities and emphasize clinical value can obtain Recognition of the capital market
.
It can also be seen that the capital market is more inclined to pharmaceutical companies with independent innovation capabilities.
Although the license in model is conducive to accelerating the expansion of pharmaceutical companies’ product pipelines, if they rely on this model for a long time, the R&D and innovation capabilities of pharmaceutical companies may also be possible.
It is difficult to gain recognition from the capital market
.
Under this background, the number of domestic biomedical innovation companies has increased day by day, and the research and development of new drugs has high R&D investment, high risk, and payback period.
In order to solve the dilemma of insufficient innovation, more and more pharmaceutical companies have introduced innovative projects through the "authorized introduction" model to further enrich their product lines in addition to independent research and development
.
It is understood that since September, many pharmaceutical companies have introduced a variety of innovative drugs from outside
.
For example, on September 28th, Cinda Bio announced that it has reached a strategic cooperation with unio Therapeutics on unio's main drug candidate orismilast for the treatment of inflammatory skin diseases
.
According to the terms of the agreement, Cinda Bio will obtain the exclusive rights to research, development and commercialization of orismilast in China
.
unio will receive a down payment of 20 million U.
S.
dollars and is entitled to a cumulative milestone payment of no more than 247 million U.
S.
dollars, as well as royalties for the annual net sales of orismilast in China
.
Haisco announced on the evening of September 13 that the company and Biosplice Therapeutics, Inc.
of the United States signed a cooperation agreement with Lorecivivint, a candidate for a long-term treatment of osteoarthritis
.
According to the agreement, Haisco obtained the exclusive right to be responsible for Lorecivivint's development, registration and commercialization activities in China
.
To this end, Haisco will pay Biosplice US$20 million in down payment and registration mileage, as well as certain commercial mileage and royalties based on future sales, with a total transaction amount of US$140 million
.
On September 16, Saisheng Pharmaceuticals announced that the company has reached a cooperation and licensing agreement with Tarveda Therapeutics, which will serve as the latter's exclusive partner in the development, production and commercialization of Greater China (including China, Hong Kong, Macau and Taiwan) New product portfolio of small molecule conjugated drugs
.
According to the agreement, Saisheng Pharmaceutical will pay a down payment to Tarveda and have the right to make equity investment in the latter
.
According to the statistics of Minai.
com, since 2021, there have been more than 90 domestic innovative drug license in projects, of which more than 30 transactions exceeded 100 million U.
S.
dollars, and 14 exceeded 300 million U.
S.
dollars
.
The industry pointed out that license in has become one of the rapid development methods for many innovative pharmaceutical companies, which has also made the “authorized introduction” model of innovative drugs popular
.
However, such pharmaceutical companies also face many tests, including their ability to judge drugs and BD levels, as well as domestic clinical advancement and sales capabilities
.
It is also worth mentioning that the regulators and the market have also been quite cautious about the license in mode
.
In September of this year, Haihe Pharmaceutical's IPO was officially rejected
.
Within a week, GK Gene's IPO was also rejected
.
Since the beginning of this year, the number of biomedical entrepreneurs who terminated the IPO on the Sci-tech Innovation Board has increased to 14
.
Judging from the Shanghai Stock Exchange’s announcement, the supervisory authority has doubts about the “scientific innovation content” of Jikai Gene and Haihe Medicine, and believes that the issuer has not fully disclosed its independent research and development capabilities and technological advancement
.
In this regard, the industry believes that under the background of emphasizing "hard technology", in the future, it will be difficult for biopharmaceutical companies with a lack of scientific and technological innovation to go public.
Only biopharmaceutical companies that focus on innovation capabilities and emphasize clinical value can obtain Recognition of the capital market
.
It can also be seen that the capital market is more inclined to pharmaceutical companies with independent innovation capabilities.
Although the license in model is conducive to accelerating the expansion of pharmaceutical companies’ product pipelines, if they rely on this model for a long time, the R&D and innovation capabilities of pharmaceutical companies may also be possible.
It is difficult to gain recognition from the capital market
.
